Previous studies have suggested that continuously active HER2 downstream signalling pathways, including the PI3K and MAPK pathways, might result in the relatively lower sensitivity of trastuzumab in HER2-positive GC than in HER2-positive breast cancer [35, 36]. Here, ERBB2 is linked to breast carcinoma.